Targeting this axis—via HIF-1α inhibitors, NRF2 pathway modulators or mitochondrial metabolism blockers—may re-sensitize CCA to immune-checkpoint inhibitors and shift the TME from suppressive to permissive (Figure 7). Here, HIF1A is linked to cholangiocarcinoma.